Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxazepam
Drug ID BADD_D01636
Description Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.[L13895]
Indications and Usage Oxazepam is indicated for the management of anxiety disorders and for the short-term relief of symptoms of anxiety.[L13895] It may also be used in the management of alcohol withdrawal symptoms.[L13895]
Marketing Status approved
ATC Code N05BA04
DrugBank ID DB00842
KEGG ID D00464
MeSH ID D010076
PubChem ID 4616
TTD Drug ID D09LDR
NDC Product Code 64330-015; 12828-0024; 43353-965; 52817-292; 71610-639; 62584-814; 48087-0087; 72166-009; 43353-980; 52817-291; 62584-813; 0228-2073; 62584-812; 0228-2069; 0228-2067; 52817-290
UNII 6GOW6DWN2A
Synonyms Oxazepam | Serax | Tazepam | Adumbran
Chemical Information
Molecular Formula C15H11ClN2O2
CAS Registry Number 604-75-1
SMILES C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicide attempt19.12.01.0040.015958%
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.0070.003800%-
Tension19.06.02.0050.003040%-
Tremor17.01.06.0020.006839%
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Mobility decreased08.01.03.030; 15.03.05.023; 17.02.05.0180.001520%-
Paradoxical drug reaction08.06.01.014---
Psychomotor skills impaired17.02.10.005; 19.22.01.0020.001520%-
General physical health deterioration08.01.03.0180.004103%-
Balance disorder08.01.03.081; 17.02.02.007---
Deep vein thrombosis24.01.02.0030.001520%-
Musculoskeletal stiffness15.03.05.0270.001520%-
Bronchopneumopathy22.02.07.0100.002280%-
Foetal death08.04.01.011; 18.01.02.0030.001520%
Cognitive disorder17.03.03.003; 19.21.02.0010.003040%
Freezing phenomenon17.01.05.0060.002280%-
Appetite disorder14.03.01.004; 19.09.01.0020.001520%-
Libido disorder19.08.03.004; 21.03.02.006---
Mental disorder19.07.01.0020.001520%-
Motor dysfunction15.05.06.006; 17.01.02.031---
Abnormal behaviour19.01.01.0010.001520%-
Parkinson's disease17.01.05.0100.001520%-
Blood disorder01.05.01.004---
Psychotic disorder19.03.01.0020.001520%
Unevaluable event08.01.03.0510.001520%-
Poor quality sleep17.15.04.002; 19.02.05.0050.002280%-
Psychiatric decompensation19.01.02.0100.001520%-
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages